^
    Back
    Association details:
    Biomarker:TNFRSF14 overexpression
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    SITC 2021
    Title:

    Predictive soluble biomarkers of immune response to checkpoint blockade in non-small cell lung cancer (NSCLC) patients

    Published date:
    11/09/2021
    Excerpt:
    Interestingly, significant upregulation of GITR (<0.0005***), PD-L1 (<0.002**) and HVEM (<0.006**) was observed in responding patients...The study demonstrates that 10 markers show differences in NSCLC patients as compared to healthy controls; 2 markers as surrogates for tissue PDL-1 and 3 markers as predictive biomarkers of response to ICB treatment.
    DOI:
    10.1136/jitc-2021-SITC2021.017